NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.73 +0.13 (+0.55 %)
(As of 11/21/2018 03:07 AM ET)
Previous Close$23.60
Today's Range$22.80 - $23.93
52-Week Range$12.70 - $25.07
Volume627,100 shs
Average Volume686,040 shs
Market Capitalization$1.25 billion
P/E Ratio-67.80
Dividend YieldN/A
Beta1.06
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
Previous Symbol
CUSIP92165910
Phone202-734-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio6.03
Quick Ratio6.01

Price-To-Earnings

Trailing P/E Ratio-67.80
Forward P/E Ratio113.00
P/E Growth3.25

Sales & Book Value

Annual Sales$165.08 million
Price / Sales7.54
Cash FlowN/A
Price / CashN/A
Book Value$2.92 per share
Price / Book8.13

Profitability

EPS (Most Recent Fiscal Year)($0.35)
Net Income$-15,560,000.00
Net Margins7.06%
Return on Equity5.88%
Return on Assets4.57%

Miscellaneous

Employees273
Outstanding Shares52,450,000
Market Cap$1.25 billion
OptionableOptionable

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.18. The biopharmaceutical company earned $49.13 million during the quarter, compared to the consensus estimate of $49.44 million. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The firm's quarterly revenue was up 18.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.03) earnings per share. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Vanda Pharmaceuticals.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180-200 million, compared to the consensus revenue estimate of $192.44 million.

What price target have analysts set for VNDA?

7 analysts have issued 1 year price targets for Vanda Pharmaceuticals' shares. Their forecasts range from $26.00 to $31.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $28.8333 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

What is the consensus analysts' recommendation for Vanda Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vanda Pharmaceuticals.

What are Wall Street analysts saying about Vanda Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (11/17/2018)
  • 2. Stifel Nicolaus analysts commented, "We reiterate our Buy rating and $30 target price. All relevant disclosures and certifications appear on pages 3 – 5 of this report. Stifel does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.Investment Thesis We believe Vanda’s current valuation is an attractive entry point for investors, given its accelerating base business and relatively de-risked, late-stage pipeline that we believe is under-appreciated." (10/31/2018)
  • 3. Cantor Fitzgerald analysts commented, "We are Neutral on VNDA with a 12-month PT of $26. HETLIOZ is delivering consistent growth in non-24, approaching the $100M threshold in net revs, which we view as an inflection point in broadening institutional interest. However, our Neutral rating results from the lack of visibility on the tradipitant P3 program for neuropathic itch (i.e., pruritus) in atopic dermatitis and meaningful pipeline-driven growth. Although we believe that the program has an increased PoS resulting from a P3 design well-informed by P2 data, in our view, enhanced clarity on timelines is needed to become more constructive." (10/3/2018)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

Media headlines about VNDA stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,165,882 shares, an increase of 89.1% from the September 28th total of 2,203,512 shares. Based on an average daily volume of 805,294 shares, the short-interest ratio is presently 5.2 days. Approximately 8.2% of the shares of the company are sold short. View Vanda Pharmaceuticals' Current Options Chain.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 58)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 52)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 49)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 52)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.89%), Macquarie Group Ltd. (5.11%), Renaissance Technologies LLC (3.91%), Glenmede Trust Co. NA (3.37%), FMR LLC (2.13%) and First Manhattan Co. (1.58%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Which institutional investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Stonepine Capital Management LLC, FMR LLC, First Manhattan Co., Alambic Investment Management L.P., Man Group plc, Prudential Financial Inc. and Credit Suisse AG. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.

Which institutional investors are buying Vanda Pharmaceuticals stock?

VNDA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Glenmede Trust Co. NA, Wells Fargo & Company MN, Bank of New York Mellon Corp, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Acadian Asset Management LLC and Arizona State Retirement System. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $23.73.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $1.25 billion and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is http://www.vandapharmaceuticals.com.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel